Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENTX vs ENSC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: ENTX 3 – 2 ENSC (1 Tie) Matrix Metrics: ENTX 6 – 4 ENSC

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin), whereas ENSC carries 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin).

  • Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -281.3% operating margin) and revenue trajectory (-100.0% vs. -15.1% YoY).
  • Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTX vs ENSC
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap $571.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 53% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 52.0 Fund 49.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 61
RSI-14: 61.2 · SMA20: $3.13 · SMA50: $2.93
ENSC NASDAQ
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44

6-Pillar Scorecard Institutional Category Breakdown (ENTX 3 – 2 ENSC)

Columns: Metric · ENTX · ENSC
1. Valuation Multiples ENSC
Forward P/E N/M 0.8x
Trailing P/E N/M 0.8x
PEG Ratio N/M N/M
EV / Revenue N/M 1.4x
2. Growth & Scale ENSC
Revenue Growth (YoY) -100.0% -15.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.5M
Market Cap $571.2M $7.0M
3. Profitability & Quality ENTX
Gross Margin N/A N/A
Operating Margin 0.0% -281.3%
Net Profit Margin 0.0% -280.5%
Return on Equity (ROE) -20.3% -1295.1%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$16M -$9.7M
Cash Flow Margin N/A N/A
Net Cash / Leverage $265M Net Cash -$499,633 Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 116.0% (33rd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTX (6) vs ENSC (4)
Institutional Metric ENTX ENSC Criterion Row Edge
Market Capitalization
Scale
$571.2M $7.0M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M 0.8x Lower Multiple ENSC
Forward P/E Ratio
Valuation
N/M 0.8x Lower Multiple ENSC
Revenue Growth (YoY)
Growth
-100.0% -15.1% Higher Growth ENSC
Operating Margin (TTM)
Profitability
0.0% -281.3% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% -280.5% Higher Margin ENTX
Return on Equity (ROE)
Capital Efficiency
-20.3% -1295.1% Higher ROE ENTX
52-Week Range Position
Momentum
73% ($1–$4) 8% ($0–$2) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
0.92β · 53% Vol 0.98β · 79% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 53.4 / 100 (HOLD) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash) -$9.7M (-$499,633 Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +38.99 pp
ENTX: +9.44% · ENSC: -29.55%
3M Horizon ENSC +3.08 pp
ENTX: -3.36% · ENSC: -0.28%
6M Horizon ENTX +153.54 pp
ENTX: +166.53% · ENSC: +12.99%
1Y Horizon ENTX +105.05 pp
ENTX: +24.72% · ENSC: -80.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTX Revenue ENSC Revenue ENTX Op. Margin ENSC Op. Margin Margin Leader
FY2020 $0M $0M -3059.7% -41.0% ENSC
FY2021 $0M $0M -2139.6% -562.7% ENSC
FY2022 $0M $0M -9714.2% -959.9% ENSC
FY2023 N/A $0M N/A -480.5% ENSC
FY2024 $0M $10M -5295.6% -129.2% ENSC
FY2025 $0M $10M -27450.0% -202.1% ENSC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTX CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 116.0%
IV Percentile 33rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $571.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTX vs ENSC Key Questions & Quantitative Answers

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin), whereas ENSC carries 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin). Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -281.3% operating margin) and revenue trajectory (-100.0% vs. -15.1% YoY). Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ENSC leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENSC at -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENTX cumulative revenue shifted N/A while ENSC shifted +0.0%. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENSC.

ENSC screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus ENSC (-1295.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk). By comparison, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.